Vertex Pharmaceuticals (VRTX) AI Stock Analysis

Vertex Pharmaceuticals

(BMV:VRTX)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong profitability and cash generationVertex converts a large share of reported earnings into operating and free cash flow, supporting internally funded research, commercial investment, acquisitions, and shareholder returns. This cash-generation profile, alongside high margins, provides resilience and financial capacity over the next several quarters.

Negative Factors

Acquisition-related debt and financing costsThe Crinetics acquisition has increased leverage and recurring financing costs, reducing the cash available for innovation, commercial expansion, or shareholder returns. These obligations can weigh on earnings and financial flexibility through the integration period, even though the broader balance sheet remains strong.

Vertex Pharmaceuticals (VRTX) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 141.65B
Dividend Yield: ―
Average Volume (3M): 327
Price to Earnings (P/E): 35.3
Beta (1Y): -0.07
Revenue Growth: 1.45%
EPS Growth: 12.10%
Country: Mexico
Employees: 6,400
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Vertex Pharmaceuticals Business Overview & Revenue Model

Company Description

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for...

Vertex Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 01, 2026(Q3-2026)|Next Earnings Date:Feb 08, 2027

Earnings Call SentimentPositive

The call was strongly positive, with 12% year-over-year revenue growth, raised full-year revenue guidance, strong commercial momentum across ALYFTREK, CASGEVY, JOURNAVX, and Palsonify, substantial pipeline advancement, and readiness for the povitacept IgAN launch. The main challenges were higher operating and financing costs related to the Crinetics acquisition, temporary JOURNAVX gross-to-net pressure, and the lack of sweat-chloride improvement in the VX-828 dual-combination cohort, but these were outweighed by the reported commercial and clinical progress.

Positive Updates

Strong Third-Quarter Revenue Growth

Third-quarter total revenue grew 12% year over year, with growth of 10% in the US and 16% internationally. Results included an approximately 1 percentage point favorable impact from foreign exchange and $10 million of revenue from Crinetics following the acquisition close.

Negative Updates

Higher Operating Expenses Following Crinetics Acquisition

Third-quarter non-GAAP SG&A expense increased 51% year over year to $556 million, with nearly 80% of the incremental spend used to enhance commercial capabilities. Full-year combined non-GAAP operating-expense guidance was raised from $5.65 billion to $5.75 billion to approximately $6 billion, including approximately $250 million of Crinetics operating expenses and integration-related costs.

Company Guidance

Vertex raised total revenue guidance from $13.1 billion to $13.2 billion to $13.15 billion to $13.25 billion, including $40 million to $50 million from Crinetics, more than $500 million in revenue from CASGEVY and JOURNAVX, 4 months of Palsonify, and an expected full year benefit from foreign exchange of roughly 150 basis points; full year gross margins are expected to be slightly below 86%, combined non GAAP operating expense guidance was revised from $5.65 billion to $5.75 billion to approximately $6 billion, including approximately $250 million of Crinetics operating expenses and integration related costs, total nonoperating costs are expected to be $105 million, interest income is projected to be approximately $60 million lower, and the full year non GAAP effective tax rate is expected to be between 19.5% and 20.5%.

Vertex Pharmaceuticals Risk Analysis

Vertex Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Vertex Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

2 New Risks

1.Special note regarding forward-looking statementsQ3, 2025

2.The information presented below supplements the risk factors set forth in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 13, 2025. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K.Q3, 2025

Vertex Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:VRTX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALNY	71Outperform	$22.10B	7.75	159.72%	―	56.17%	6459.20%
BMRN	58Neutral	$11.33B	-638.22	1.18%	―	13.69%	-89.03%
NTLA	58Neutral	$1.75B	-3.47	-57.79%	―	12.58%	28.42%
SRPT	58Neutral	$1.97B	-12.72	-9.96%	―	-20.44%	-349.84%
CRSP	56Neutral	$4.97B	-10.55	-24.39%	―	-64.80%	12.20%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:VRTX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:VRTX	Vertex Pharmaceuticals Inc.	10130.00	2150.00	26.94%
ALNY	Alnylam Pharmaceuticals	158.00	-265.47	-62.69%
BMRN	Biomarin Pharmaceutical Inc.	57.44	4.92	9.37%
SRPT	Sarepta Therapeutics Inc.	18.32	2.12	13.09%
NTLA	Intellia Therapeutics Inc	11.66	-0.54	-4.43%
CRSP	Crispr Therapeutics	49.99	-6.42	-11.38%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Vertex Pharmaceuticals AI Stock Analysis